219 related articles for article (PubMed ID: 20374626)
21. Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C.
Schumann C; Triantafilou K; Kamenz J; Hanke H; Triantafilou M; Wittemann S; Joos T; Hombach V; Schneider EM; Lepper PM
Scand J Infect Dis; 2006; 38(2):139-42. PubMed ID: 16449010
[TBL] [Abstract][Full Text] [Related]
22. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.
Vincent JL; O'Brien J; Wheeler A; Wittebole X; Garg R; Trzaskoma BL; Sundin DP
Crit Care; 2006; 10(3):R74. PubMed ID: 16684364
[TBL] [Abstract][Full Text] [Related]
23. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W
Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322
[TBL] [Abstract][Full Text] [Related]
24. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
Dhainaut JF;
Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
[TBL] [Abstract][Full Text] [Related]
25. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
26. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
Short MA; Schlichting D; Qualy RL
Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
[TBL] [Abstract][Full Text] [Related]
27. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
Dhainaut JF; Antonelli M; Wright P; Desachy A; Reignier J; Lavoue S; Charpentier J; Belger M; Cobas-Meyer M; Maier C; Mignini MA; Janes J
Intensive Care Med; 2009 Jul; 35(7):1187-95. PubMed ID: 19263034
[TBL] [Abstract][Full Text] [Related]
28. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
[TBL] [Abstract][Full Text] [Related]
29. Drotrecogin alfa (activated): real-life use and outcomes for the UK.
Rowan KM; Welch CA; North E; Harrison DA
Crit Care; 2008; 12(2):R58. PubMed ID: 18430215
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
[TBL] [Abstract][Full Text] [Related]
31. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
32. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
[TBL] [Abstract][Full Text] [Related]
33. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
[TBL] [Abstract][Full Text] [Related]
34. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.
Hodder RV; Hall R; Russell JA; Fisher HN; Lee B
Crit Care; 2009; 13(3):R78. PubMed ID: 19457240
[TBL] [Abstract][Full Text] [Related]
35. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.
Bilbault P; Lavaux T; Launoy A; Gaub MP; Meyer N; Oudet P; Pottecher T; Jaeger A; Schneider F
Crit Care Med; 2007 Jan; 35(1):69-75. PubMed ID: 17133181
[TBL] [Abstract][Full Text] [Related]
36. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
[TBL] [Abstract][Full Text] [Related]
37. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis.
Levy H; Small D; Heiselman DE; Riker R; Steingrub J; Chen R; Qualy RL; Darstein C; Mongan E
Ann Pharmacother; 2005 Feb; 39(2):262-7. PubMed ID: 15632220
[TBL] [Abstract][Full Text] [Related]
38. Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL
Curr Drug Saf; 2007 Sep; 2(3):227-31. PubMed ID: 18690972
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock.
Nguyen DN; Spapen H; Su F; Schiettecatte J; Shi L; Hachimi-Idrissi S; Huyghens L
Crit Care Med; 2006 Jul; 34(7):1967-74. PubMed ID: 16607230
[TBL] [Abstract][Full Text] [Related]
40. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]